These data indicate that a dysregulated immune response of the airway epithelium, seen particularly in patients with severe asthma, can be targeted by the inhibition of TSLP, which also results in reduced levels of IL-33 and T2 cytokines. The gene discussed is TSLP; the disease is asthma.